Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production

• US RE46,788 E1
• Filed: 05/20/2016
• Issued: 04/17/2018
• Est. Priority Date: 02/21/2006
• Status: Active Grant

• Current Assignee: Isp Investments LLC (Ashland Global Holdings, Inc.)
• Original Assignee: Isp Investments LLC (Ashland Global Holdings, Inc.)
• Inventors: Koganov, Michael
• Primary Examiner(s): CAMPELL, BRUCE R
• Application Number:
  US15/161,134
• Time in Patent Office: 697 Days
• CPC Class Codes: A61K 36/28 Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea

Abstract

The present invention relates to bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant. The bioactive fractions are either free of or substantially free of α-unsaturated γ-lactones (e.g., parthenolide). Further, the bioactive fractions have anti-inflammatory and antioxidant activity. The present invention also relates to a method for isolating a bioactive fraction that is derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant and that is at least substantially free of α-unsaturated γ-lactones (e.g., parthenolide). The present invention also relates to a method for preparing a stabilized cell juice serum fraction and a stabilized concentrated cell juice serum fraction that are free of α-unsaturated γ-lactones (e.g., parthenolide). The present invention also relates to a bioactive composition that includes a mixture of one or more of the isolated bioactive fractions of the present invention.

Claims

1. A bioactive ingredient having anti-inflammatory activity comprising a cytoplasm fraction precipitate derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant, wherein said cytoplasm fraction precipitate is produced by the process comprising:

providing fresh biomass of a feverfew (Tanacetum parthenium) plant;

processing the fresh biomass under conditions effective to yield a cell juice supernatant and a membrane fraction;

treating the cell juice supernatant under conditions effective to yield a first cell juice serum supernatant and a cytoplasm fraction precipitate; and

isolating the cytoplasm fraction precipitate, wherein said cytoplasm fraction precipitate is a bioactive fraction that is substantially free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide.

2. A bioactive ingredient having anti-inflammatory activity comprising a stabilized cell juice serum fraction derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant, wherein said stabilized cell juice serum fraction is produced by a process comprising:

providing fresh biomass of a feverfew (Tanacetum parthenium) plant;

processing the fresh biomass under conditions effective to yield a cell juice supernatant and a membrane fraction;

treating the cell juice supernatant under conditions effective to yield a first cell juice serum supernatant and a cytoplasm fraction precipitate;

clarifying the first cell juice serum supernatant under conditions effective to yield a second cell juice serum supernatant; and

mixing a stabilizing agent with the second cell juice serum supernatant under conditions effective to yield a stabilized cell juice serum fraction,

wherein said stabilized cell juice serum fraction is a bioactive fraction that is either free of α

-unsaturated γ

-lactones or substantially free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide.

3. The bioactive ingredient according to claim 2, wherein said stabilized cell juice serum fraction has an anti-inflammatory activity ranging from an IC₅₀ value of between about 0.01 percent (volume by volume) and about 2.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of elastase enzymatic reaction by 50 percent.

4. The bioactive ingredient according to claim 2, wherein said stabilized cell juice serum fraction has an antioxidant activity ranging from an IC₅₀ value of between about 0.007 percent (volume by volume) and about 1.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of cytochrome c reduction by 50 percent.

5. A bioactive ingredient having anti-inflammatory activity comprising a stabilized concentrated cell juice serum fraction derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant, wherein said stabilized concentrated cell juice serum fraction is produced by a process comprising:

providing fresh biomass of a feverfew (Tanacetum parthenium) plant;

processing the fresh biomass under conditions effective to yield a cell juice supernatant and a membrane fraction;

treating the cell juice supernatant under conditions effective to yield a first cell juice serum supernatant and a cytoplasm fraction precipitate;

clarifying the first cell juice serum supernatant under conditions effective to yield a second cell juice serum supernatant;

mixing a stabilizing agent with the second cell juice serum supernatant under conditions effective to yield a stabilized cell juice serum fraction;

concentrating the stabilized cell juice serum fraction under conditions effective to yield a concentrated cell juice serum supernatant; and

mixing a stabilizing agent with the concentrated cell juice serum supernatant under conditions effective to yield a stabilized concentrated cell juice serum fraction,

wherein said stabilized concentrated cell juice serum fraction is a bioactive fraction that is free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide.

6. The bioactive ingredient according to claim 5, wherein said stabilized concentrated cell juice serum fraction has an anti-inflammatory activity ranging from an IC₅₀ value of between about 0.01 percent (volume by volume) and about 2.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of elastase enzymatic reaction by 50 percent.

7. The bioactive ingredient according to claim 5, wherein said stabilized concentrated cell juice serum fraction has an antioxidant activity ranging from an IC₅₀ value of between about 0.007 percent (volume by volume) and about 1.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of cytochrome c reduction by 50 percent.